CareDx

CareDx

CareDx

AlloMap is a way to non-invasively test cardiac transplant patients for their risk of acute cellular rejection, graft failure, and death.
Founded
2000
Raised
$150M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$25,000,000
Post-IPO debt - 2017
$22,170,000
Post-IPO equity - 2016
Team Size
50+
Employees
FinSMEs

CareDx Buys XynManagement

$25,000,000 Post-IPO debt
GlobeNewswire News Room

CareDx Closes New $25 Million Debt Facility